

Potential Financial Impact of the Inflation Reduction Act for Patients with Advanced Prostate Cancer

Ben Pockros MD, MBA¹, Kristian Stensland MD MPH MS¹, Vahakn Shahinian MD¹
 Department of Urology, Michigan Medicine¹



Background

- Oral androgen-targeted medications have dramatically improved the standard of care for patients with advanced prostate cancer, but they come with significant costs.
- The Inflation Reduction Act (IRA) was signed into law in August 2022 with the following provisions for Medicare beneficiaries:

\$2,000 OOP Cap per Year
 (starting 2025)


Drug Price Negotiations
 (starting 2026)

- We evaluate the potential impact of the IRA for patients with advanced prostate cancer.

Methods

- All Medicare data obtained from 2021 Medicare Part D Dashboard.
- Projections based off specific provisions from the 2022 IRA.

Findings



*Medicare spent over \$4 billion dollars on 75,000 oral androgen-targeted prescriptions in 2021.

**Enzalutamide price negotiations projected to start in 2027. Apalutamide and Darolutamide projected for 2028.

Future Policy Considerations

- Impact on innovation?
- Will improved affordability lead to increased prescription activity beyond evidence of clinical benefit?
- Will the Pharmaceutical Industry take legal action?

Conclusions

- IRA is projected to save thousands of dollars in out-of-pocket drug costs for patients with advanced prostate cancer starting in 2025.
- Multiple anti-androgen agents are projected to be selected for price negotiations in the upcoming 5 years.
- Patients under 65 with commercial insurance remain vulnerable to high OOP drug expenses.

